BUZZ-Australia's Invion gains on new medical technology license** Shares of Invion IVX.AX rise as much as 39.2% to A$0.110, rising most since August 19
** Biotech co secures an expanded portfolio of perpetual exclusive global licenses to the Photosoft technology
** Photosoft platform licenses cover a broad portfolio of human and animal diseases, including cancers and infectious diseases
** Stock at highest since October 16
** Over 389,000 shares change hands, compared with the 30-day average volume of 49,486
** Stock currently up 32.9%, bringing YTD losses to 62.5%
(Reporting by Adwitiya Srivastava in Bengaluru)
((Adwitiya.Srivastava@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.